Cargando…
Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives
PURPOSE: To review how outcomes of clinical utility are operationalized in current amyloid-PET validation studies, to prepare for formal assessment of clinical utility of amyloid-PET-based diagnosis. METHODS: Systematic review of amyloid-PET research studies published up to April 2020 that included...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175294/ https://www.ncbi.nlm.nih.gov/pubmed/33594474 http://dx.doi.org/10.1007/s00259-020-05187-x |
_version_ | 1783703023951806464 |
---|---|
author | Cotta Ramusino, Matteo Perini, Giulia Altomare, Daniele Barbarino, Paola Weidner, Wendy Salvini Porro, Gabriella Barkhof, Frederik Rabinovici, Gil D. van der Flier, Wiesje M. Frisoni, Giovanni B. Garibotto, Valentina Teipel, Stefan Boccardi, Marina |
author_facet | Cotta Ramusino, Matteo Perini, Giulia Altomare, Daniele Barbarino, Paola Weidner, Wendy Salvini Porro, Gabriella Barkhof, Frederik Rabinovici, Gil D. van der Flier, Wiesje M. Frisoni, Giovanni B. Garibotto, Valentina Teipel, Stefan Boccardi, Marina |
author_sort | Cotta Ramusino, Matteo |
collection | PubMed |
description | PURPOSE: To review how outcomes of clinical utility are operationalized in current amyloid-PET validation studies, to prepare for formal assessment of clinical utility of amyloid-PET-based diagnosis. METHODS: Systematic review of amyloid-PET research studies published up to April 2020 that included outcomes of clinical utility. We extracted and analyzed (a) outcome categories, (b) their definition, and (c) their methods of assessment. RESULTS: Thirty-two studies were eligible. (a) Outcome categories were clinician-centered (found in 25/32 studies, 78%), patient-/caregiver-centered (in 9/32 studies, 28%), and health economics-centered (5/32, 16%). (b) Definition: Outcomes were mainly defined by clinical researchers; only the ABIDE study expressly included stakeholders in group discussions. Clinician-centered outcomes mainly consisted of incremental diagnostic value (25/32, 78%) and change in patient management (17/32, 53%); patient-/caregiver-centered outcomes considered distress after amyloid-pet-based diagnosis disclosure (8/32, 25%), including quantified burden of procedure for patients’ outcomes (n = 8) (1/8, 12.5%), impact of disclosure of results (6/8, 75%), and psychological implications of biomarker-based diagnosis (75%); and health economics outcomes focused on costs to achieve a high-confidence etiological diagnosis (5/32, 16%) and impact on quality of life (1/32, 3%). (c) Assessment: all outcome categories were operationalized inconsistently across studies, employing 26 different tools without formal rationale for selection. CONCLUSION: Current studies validating amyloid-PET already assessed outcomes for clinical utility, although non-clinician-based outcomes were inconsistent. A wider participation of stakeholders may help produce a more thorough and systematic definition and assessment of outcomes of clinical utility and help collect evidence informing decisions on reimbursement of amyloid-PET. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-020-05187-x. |
format | Online Article Text |
id | pubmed-8175294 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-81752942021-06-17 Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives Cotta Ramusino, Matteo Perini, Giulia Altomare, Daniele Barbarino, Paola Weidner, Wendy Salvini Porro, Gabriella Barkhof, Frederik Rabinovici, Gil D. van der Flier, Wiesje M. Frisoni, Giovanni B. Garibotto, Valentina Teipel, Stefan Boccardi, Marina Eur J Nucl Med Mol Imaging Review Article PURPOSE: To review how outcomes of clinical utility are operationalized in current amyloid-PET validation studies, to prepare for formal assessment of clinical utility of amyloid-PET-based diagnosis. METHODS: Systematic review of amyloid-PET research studies published up to April 2020 that included outcomes of clinical utility. We extracted and analyzed (a) outcome categories, (b) their definition, and (c) their methods of assessment. RESULTS: Thirty-two studies were eligible. (a) Outcome categories were clinician-centered (found in 25/32 studies, 78%), patient-/caregiver-centered (in 9/32 studies, 28%), and health economics-centered (5/32, 16%). (b) Definition: Outcomes were mainly defined by clinical researchers; only the ABIDE study expressly included stakeholders in group discussions. Clinician-centered outcomes mainly consisted of incremental diagnostic value (25/32, 78%) and change in patient management (17/32, 53%); patient-/caregiver-centered outcomes considered distress after amyloid-pet-based diagnosis disclosure (8/32, 25%), including quantified burden of procedure for patients’ outcomes (n = 8) (1/8, 12.5%), impact of disclosure of results (6/8, 75%), and psychological implications of biomarker-based diagnosis (75%); and health economics outcomes focused on costs to achieve a high-confidence etiological diagnosis (5/32, 16%) and impact on quality of life (1/32, 3%). (c) Assessment: all outcome categories were operationalized inconsistently across studies, employing 26 different tools without formal rationale for selection. CONCLUSION: Current studies validating amyloid-PET already assessed outcomes for clinical utility, although non-clinician-based outcomes were inconsistent. A wider participation of stakeholders may help produce a more thorough and systematic definition and assessment of outcomes of clinical utility and help collect evidence informing decisions on reimbursement of amyloid-PET. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-020-05187-x. Springer Berlin Heidelberg 2021-02-17 2021 /pmc/articles/PMC8175294/ /pubmed/33594474 http://dx.doi.org/10.1007/s00259-020-05187-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Article Cotta Ramusino, Matteo Perini, Giulia Altomare, Daniele Barbarino, Paola Weidner, Wendy Salvini Porro, Gabriella Barkhof, Frederik Rabinovici, Gil D. van der Flier, Wiesje M. Frisoni, Giovanni B. Garibotto, Valentina Teipel, Stefan Boccardi, Marina Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives |
title | Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives |
title_full | Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives |
title_fullStr | Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives |
title_full_unstemmed | Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives |
title_short | Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives |
title_sort | outcomes of clinical utility in amyloid-pet studies: state of art and future perspectives |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175294/ https://www.ncbi.nlm.nih.gov/pubmed/33594474 http://dx.doi.org/10.1007/s00259-020-05187-x |
work_keys_str_mv | AT cottaramusinomatteo outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives AT perinigiulia outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives AT altomaredaniele outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives AT barbarinopaola outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives AT weidnerwendy outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives AT salviniporrogabriella outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives AT barkhoffrederik outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives AT rabinovicigild outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives AT vanderflierwiesjem outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives AT frisonigiovannib outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives AT garibottovalentina outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives AT teipelstefan outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives AT boccardimarina outcomesofclinicalutilityinamyloidpetstudiesstateofartandfutureperspectives |